List of disorders included in newborn screening programs

This is a list of disorders included in newborn screening programs around the world, along with information on testing methodologies, disease incidence and rationale for being included in screening programs.

American College of Medical Genetics recommendations

Core panel

The following conditions and disorders were recommended as a "core panel" by the 2005 report of the American College of Medical Genetics (ACMG).[1] The incidences reported below are from the full report, though the rates may vary in different populations.[2]

Blood cell disorders

  • Sickle cell anemia (Hb SS) > 1 in 5,000; among African-Americans 1 in 400
  • Sickle-cell disease (Hb S/C) > 1 in 25,000
  • Hb S/Beta-Thalassemia (Hb S/Th) > 1 in 50,000

Inborn errors of amino acid metabolism

Inborn errors of organic acid metabolism

Inborn errors of fatty acid metabolism

  • Long-chain hydroxyacyl-CoA dehydrogenase deficiency (LCHAD) > 1 in 75,000
  • Medium-chain acyl-CoA dehydrogenase deficiency (MCAD) > 1 in 25,000
  • Very-long-chain acyl-CoA dehydrogenase deficiency (VLCAD) > 1 in 75,000
  • Trifunctional protein deficiency (TFP) < 1 in 100,000
  • Carnitine uptake defect (CUD) < 1 in 100,000

Miscellaneous multisystem diseases


Newborn screening by other methods than blood testing


Secondary targets

The following disorders are additional conditions that may be detected by screening. Many are listed as "secondary targets" by the 2005 ACMG report.[1] Some states are now screening for more than 50 congenital conditions. Many of these are rare and unfamiliar to pediatricians and other primary health care professionals.[1]

Blood cell disorders

Inborn errors of amino acid metabolism

Inborn errors of organic acid metabolism

Inborn errors of fatty acid metabolism

  • Medium/short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency[1]
  • Medium-chain ketoacyl-CoA thiolase deficiency[1]
  • Dienoyl-CoA reductase deficiency[1]
  • Glutaric acidemia type II[1]
  • Carnitine palmityl transferase deficiency type 1[1]
  • Carnitine palmityl transferase deficiency type 2[1]
  • Short-chain acyl-CoA dehydrogenase deficiency (SCAD)[1]
  • Carnitine/acylcarnitine Translocase Deficiency (Translocase)[1]
  • Short-chain hydroxy Acyl-CoA dehydrogenase deficiency (SCHAD)
  • Long-chain acyl-CoA dehydrogenase deficiency (LCAD)
  • Multiple acyl-CoA dehydrogenase deficiency (MADD)

Miscellaneous multisystem diseases

Disorders added after the initial panel was defined

In addition to identifying a core list of disorders that infants in the United States should be screened for, the ACMG also established a framework for nominating future conditions, and the structure under which those conditions should be considered.

gollark: And other alts.
gollark: It's a bit close to aeons, I think.
gollark: We need more time dragons. Some vague ideas:Hourglass Dragons (no idea, sounds cool)Clock Pygmies (pygmies which make clocks)Oracle Dragons (two-headed, one head can see into the past, one into the future)
gollark: You can probably trade them for non-pyro xenowyrms.
gollark: Well, our xenowyrm overlords *are* our xenowyrm overlords, after all.

References
  1. Newborn Screening Authoring Committee (2008). "Newborn Screening Expands: Recommendations for Pediatricians and Medical Homes—Implications for the System". Pediatrics. 121 (1): 192–217. doi:10.1542/peds.2007-3021. PMID 18166575.
  2. "Newborn Screening: Toward a Uniform Screening Panel and System: Main Report". Genetics in Medicine. American College of Medical Genetics. 8 (5, Supplement): 12S–252S. May 2008. doi:10.1097/01.gim.0000223467.60151.02. PMC 3109899.
  3. "Previously Nominated Conditions". Health Resources and Services Administration. Retrieved 2018-12-02.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.